Study of MiraBurst for Taste Changes During Cancer Treatment
This study is for people with solid tumor cancer who are experiencing changes in taste (dysgeusia) due to their cancer treatment. Taste changes can significantly affect quality of life, and this study aims to see if a freeze-dried miracle fruit product called MiraBurst can help. Participants will take one 300 mg MiraBurst mini-square up to four times a day before meals for 90 days. To join, you must be at least 18 years old, have a solid tumor cancer diagnosis, be on active cancer treatment, and have moderate taste changes. The study will evaluate how MiraBurst affects your taste perception at different points over the 90-day period. The current recruitment status is unclear, and the study plans to enroll 45 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific intervention. It plans to enroll 45 participants.
- What's involved
- Participants will consume one MiraBurst mini-square up to four times per day prior to each meal for 90 days. Taste perception will be measured at the start, on day 7, day 28, and day 90.
- Compensation
- Not stated in the trial record.
- Follow-up
- Taste perception will be evaluated at the start of the study, and then again on Day 7, Day 28, and Day 90.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of Freeze-Dried Miracle Fruit (MiraBurst) on Participants Receiving Cancer Treatment
At a glance
Conditions
NCT07419581
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Cleveland Clinic Foundation
Cleveland, Ohiostudy coordinator listed
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Shirley Thomas, MD, MRCP (UK), MRCP (UK) Pall Med, PGDip Pall Med · PRINCIPAL_INVESTIGATOR · Case Comprehensive Cancer Center, Cleveland Clinic
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Evaluate effect on taste perceptionBaseline (Day 1), Day 7
Taste changes will be assessed using the Chemotherapy-induced Taste Alteration Scale-English version (CiTAS-E) questionnaire. The CiTAS questionnaire is composed of 18 items. Six questions are answered on a 5-point Likert scale from 1 (Taste normal) to 5 (Unable to taste at all). Twelve questions are answered on a 5-point Likert scale from 1 (No) to 5 (Very). The items are divided into three dimensions: 1) quantitative changes in the perception of flavors (hypogeusia, ageusia), 2) qualitative changes in the perception of flavors (i.e., heterogeusia, cacogeusia), and 3) problems related to nutrition (i.e., difficulty in eating hot or fat foods). CITAS questionnaire does not include open-ended qualitative questions. They are closed ended questions which participants rate. Higher scores indicate worse symptoms.
- Evaluate effect on taste perceptionBaseline (Day 1), Day 28
Taste changes will be assessed using the Chemotherapy-induced Taste Alteration Scale-English version (CiTAS-E) questionnaire. The CiTAS questionnaire is composed of 18 items. Six questions are answered on a 5-point Likert scale from 1 (Taste normal) to 5 (Unable to taste at all). Twelve questions are answered on a 5-point Likert scale from 1 (No) to 5 (Very). The items are divided into three dimensions: 1) quantitative changes in the perception of flavors (hypogeusia, ageusia), 2) qualitative changes in the perception of flavors (i.e., heterogeusia, cacogeusia), and 3) problems related to nutrition (i.e., difficulty in eating hot or fat foods). CITAS questionnaire does not include open-ended qualitative questions. They are closed ended questions which participants rate. Higher scores indicate worse symptoms.
- Evaluate effect on taste perceptionBaseline (Day 1), Day 90
Taste changes will be assessed using the Chemotherapy-induced Taste Alteration Scale-English version (CiTAS-E) questionnaire. The CiTAS questionnaire is composed of 18 items. Six questions are answered on a 5-point Likert scale from 1 (Taste normal) to 5 (Unable to taste at all). Twelve questions are answered on a 5-point Likert scale from 1 (No) to 5 (Very). The items are divided into three dimensions: 1) quantitative changes in the perception of flavors (hypogeusia, ageusia), 2) qualitative changes in the perception of flavors (i.e., heterogeusia, cacogeusia), and 3) problems related to nutrition (i.e., difficulty in eating hot or fat foods). CITAS questionnaire does not include open-ended qualitative questions. They are closed ended questions which participants rate. Higher scores indicate worse symptoms.
- Evaluate effect on taste perceptionBaseline (Day 1), Day 120
Taste changes will be assessed using the Chemotherapy-induced Taste Alteration Scale-English version (CiTAS-E) questionnaire. The CiTAS questionnaire is composed of 18 items. Six questions are answered on a 5-point Likert scale from 1 (Taste normal) to 5 (Unable to taste at all). Twelve questions are answered on a 5-point Likert scale from 1 (No) to 5 (Very). The items are divided into three dimensions: 1) quantitative changes in the perception of flavors (hypogeusia, ageusia), 2) qualitative changes in the perception of flavors (i.e., heterogeusia, cacogeusia), and 3) problems related to nutrition (i.e., difficulty in eating hot or fat foods). CITAS questionnaire does not include open-ended qualitative questions. They are closed ended questions which participants rate. Higher scores indicate worse symptoms.